Crosstalk Between mTOR and p70S6 Kinase

The mechanistic target of rapamycin (mTOR) sits at the center of the PI3K/mTOR axis, a signaling network frequently dysregulated in human malignancies. mTOR integrates environmental cues, such as nutrient availability, growth factors, and cellular energy to coordinate anabolic processes essential for cell growth and proliferation. Traditionally, mTOR Complex 1 (mTORC1) was seen as unidirectionally activating its primary downstream effector, p70 ribosomal S6 kinase (p70S6K), recent evidence positions p70S6K as a critical determinant of therapeutic outcome. This review challenges the reductionist view of p70S6K as merely a translational regulator, exploring its mutual governance with both mTORC1 and the rapamycin-insensitive mTORC2. p70S6K functions as a feedback node modulating insulin signaling via Insulin Receptor Substrate-1 (IRS-1) and cross-regulates mTORC2 through direct phosphorylation of Rictor. In oncology, these homeostatic loops drive therapeutic resistance: pharmacological mTORC1 inhibition inadvertently relieves these brakes, reactivating survival signaling and undermining treatment durability. Furthermore, we address the functional divergence between the S6K1 and S6K2 isoforms, emphasizing the overlooked nuclear functions of S6K2 and hypothesizing that their phase-separation properties are a mechanism of adaptive stress resistance that may allow malignant cells to sequester survival signaling from pharmacological attack. Through the combined perspectives of structural biology and phosphoproteomics, we highlight recent discoveries, including the controversial physiological role of mTORC2 in phosphorylating the S6K1 hydrophobic motif and the ribosome as a physical scaffold dictating spatiotemporal signaling between mTOR complexes. Finally, we discuss how combinatorial strategies targeting this crosstalk, exemplified by the VIKTORIA-1 trial, offer more favorable therapeutic outcomes than single-node inhibition.